siplizumab + fludarabine + cyclophosphamide

**siplizumab + fludarabine + cyclophosphamide** is a combination therapy used experimentally, primarily in the context of hematologic malignancies and investigational immunosuppressive conditioning regimens. - **Siplizumab** is a humanized monoclonal antibody targeting CD2, a molecule expressed on T cells and natural killer cells, leading to immunomodulation through depletion of these cell populations by mechanisms such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. - **Fludarabine** is a purine analog and small molecule antineoplastic agent that inhibits DNA synthesis through inhibition of DNA polymerase, ribonucleotide reductase, and DNA primase. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, thereby inducing cell death, primarily in dividing cells. Together, these agents can produce profound immunosuppression and lymphodepletion, making this combination particularly relevant for conditioning in stem cell transplantation, cell therapy protocols, and treatment of hematologic cancers such as chronic lymphocytic leukemia and various T-cell leukemias[1][3][4]. Siplizumab has been associated with increased risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disease when used in heavily immunosuppressive regimens[3].

Other names

siplizumab + fludarabine + cyclophosphamide